Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will be added to the FTSE Russell Microcap® Index effective at the open of market on June 25, 2018, as part of the Russell Indexes annual reconstitution. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the applicable growth and value style indexes.

Furthermore, the Japanese Intellectual Property Office has publicized its intent to grant Oramed a patent titled, “Methods and Compositions for Oral Administration of Exenatide.” The patent covers Oramed’s proprietary invention of an oral glucagon-like peptide-1 (GLP-1) analog.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).

For more information, please visit www.oramed.com.

Source – http://www.oramed.com/category/press-releases/